Moleculin Biotech, Inc. (MBRX) Analysts See $-0.12 EPS

March 15, 2018 - By Peter Erickson

 Moleculin Biotech, Inc. (MBRX) Analysts See $ 0.12 EPS

Analysts expect Moleculin Biotech, Inc. (NASDAQ:MBRX) to report $-0.12 EPS on April, 2.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.12 EPS. After having $-0.14 EPS previously, Moleculin Biotech, Inc.’s analysts see -14.29 % EPS growth. The stock decreased 2.82% or $0.06 during the last trading session, reaching $2.07. About 280,711 shares traded. Moleculin Biotech, Inc. (NASDAQ:MBRX) has 0.00% since March 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Moleculin Biotech, Inc., a preclinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. The company has market cap of $53.32 million. The Company’s lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. It currently has negative earnings. The firm also develops other drugs, including WP1066 Portfolio that focuses on the modulation of regulatory transcription factors involved in the progression of cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma.

More recent Moleculin Biotech, Inc. (NASDAQ:MBRX) news were published by: which released: “Moleculin Biotech’s stock rockets after ‘major breakthrough’ in cancer treatment” on February 15, 2018. Also published the news titled: “Moleculin Biotech, Inc. (MBRX) and Pieris Pharmaceuticals, Inc. (PIRS …” on February 21, 2018.‘s news article titled: “Moleculin Biotech (MBRX) Prices $9 Million Registered Direct Offering” with publication date: February 16, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: